Why the study?
Does JP2 overexpression or MURF1 inhibition improve myocardial function and attenuate injury in preclinical models of heart failure?
Does JP2 overexpression or MURF1 inhibition improve myocardial function and attenuate injury in preclinical models of heart failure?
Answers are grounded in this paper and cite their sources.
Disruption of the JP2-JCN axis is an important mechanism in heart disease, and its preservation via JP2 overexpression or MURF1 inhibition offers a potential therapeutic target for cardiac protection.
Junctophilin-2 (JP2) and junctin (JCN) are key proteins in maintaining calcium homeostasis in cardiomyocytes. Both are reduced in diseased hearts while overexpression of JP2 mitigates heart failure. This study demonstrates that JP2 and JCN are reduced in cardiomyocytes under stress, leading to intracellular calcium dysregulation and subsequent cell death. JP2 binds JCN, thereby blocking muscle ring finger protein-1 (MURF1)-JCN interaction and subsequently preventing MURF1-mediated JCN ubiquitination and degradation in cardiomyocytes. Thus, JP2 overexpression and MURF1 inhibition similarly preserve JCN protein and attenuate myocardial injury and remodeling, and improve myocardial function in preclinical animal models of lipid overload-induced cardiomyopathy and transverse aortic constriction-induced heart failure. Disruption of the JP2-JCN axis represents an important mechanism underlying heart disease and may serve as a potential therapeutic target for cardiac protection.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: